← Back to Screener
Skye Bioscience, Inc. Common Stock (SKYE)
Price$0.76
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-53.90%
Price vs S&P 500 (4W)-10.81%
VGM Score28.54
Market Capitalization$27.25M
All Metrics
Book Value / Share (Quarterly)$0.26
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.21
Price vs S&P 500 (YTD)-7.55%
Gross Margin (TTM)39.29%
Net Profit Margin (TTM)-3.57%
EPS (TTM)$-1.45
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-1.45
EPS (Annual)$-1.41
ROI (Annual)-279.29%
Gross Margin (Annual)35.29%
Cash / Share (Quarterly)$0.49
ROA (Last FY)-197.52%
EBITD / Share (TTM)$-1.47
ROE (5Y Avg)-346.11%
Operating Margin (TTM)-7.14%
Cash Flow / Share (Annual)$-1.29
P/B Ratio3.02x
P/B Ratio (Quarterly)2.28x
Net Income / Employee (Annual)$-4,660,400
Net Interest Coverage (TTM)-45.68x
ROA (TTM)-162.39%
EPS Incl Extra (Annual)$-1.41
Current Ratio (Annual)3.30x
Quick Ratio (Quarterly)1.67x
3-Month Avg Trading Volume0.44M
52-Week Price Return-63.42%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.14
P/S Ratio (Annual)80.15x
Asset Turnover (Annual)2.27x
52-Week High$5.75
EPS Excl Extra (Annual)$-1.41
CapEx CAGR (5Y)-8.80%
26-Week Price Return-37.97%
Quick Ratio (Annual)3.24x
13-Week Price Return0.57%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.78x
Enterprise Value$19.15M
Asset Turnover (TTM)1.93x
Book Value / Share Growth (5Y)-36.64%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)0.00%
Cash / Share (Annual)$0.80
3-Month Return Std Dev89.08%
Net Income / Employee (TTM)$-4,777,600
ROE (Last FY)-279.29%
Net Interest Coverage (Annual)-44.71x
EPS Basic Excl Extra (Annual)$-1.41
Receivables Turnover (TTM)9.33x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-1.45
ROI (TTM)-216.75%
P/S Ratio (TTM)97.32x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.82
Price vs S&P 500 (52W)-91.63%
Year-to-Date Return3.39%
5-Day Price Return-6.50%
EPS Normalized (Annual)$-1.41
ROA (5Y Avg)-169.91%
Net Profit Margin (Annual)0.00%
Month-to-Date Return-11.77%
Cash Flow / Share (TTM)$-9.31
EBITD / Share (Annual)$-1.45
Operating Margin (Annual)0.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-130.36%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.45
P/TBV (Quarterly)11.06x
P/B Ratio (Annual)1.20x
Pretax Margin (TTM)-3.57%
Book Value / Share (Annual)$0.60
Price vs S&P 500 (13W)-9.18%
Beta2.93x
Revenue / Share (TTM)$0.00
ROE (TTM)-217.27%
52-Week Low$0.57
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.32est. -0.32
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.07
4.07
4.07
4.07
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SKYESkye Bioscience, Inc. Common Stock | — | — | D | $0.76 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Skye Bioscience is a San Diego-based pharmaceutical company developing CB1 receptor-targeted therapies for metabolic and inflammatory disorders. Lead candidates in Phase 2 are nimacimab for obesity and SBI-100 Ophthalmic Emulsion for glaucoma and ocular hypertension. The platform also targets fibrotic and neurodegenerative diseases.